Tumor-targeted therapy with a conditionally replicating mutant of HSV-1 induces regression of xenografted human hepatomas

Cancer Biology and Therapy

Volumn 4, Issue 11, 2005, Pages 1234-1239

  Xue, Feng ^a   Dong, Chang Yuan ^b   Su, Yue ^a   Zhu, Huabin ^a   Ling, Weifang ^a   Liu, Yingle ^a   Xu, Hua ^a   Xiao, Wei ^a   Zhou, Shumin ^a   Qi, Yi Peng ^a  

^a WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Cancer therapy; Hepatoma xenografts; Herpes simplex virus type 1; Icp34.5

Indexed keywords

BETA GALACTOSIDASE; DOXORUBICIN; PROBIOTIC AGENT;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPSY; BLOOD EXAMINATION; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; FIBROBLAST; GENE INSERTION; HEP 2 CELL; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARYNX CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION; VERO CELL; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION; XENOGRAFT;

EID: 33646435269     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.11.2094     Document Type: Article

References (29)

1. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Anderson WF, Ihle JN. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341:85-6.
2. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klien H, Berger M, Muller CA, Ramsey JW, Muul L, Morgan RA, Anderson WF. T lymphocyte-directed gene therapy for ADA- deficiency SCID: Initial trial results after 4 years. Science 1995; 270:475-80.
3. Ganly I, Eckhardt SG, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, VonHoff DD, Kaye SB. A phase I study of onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6:798-806.
4. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial[J]. Gene Ther 2001; 8:308-15.
5. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther 2001;8:746-59.
6. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperironeal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 7 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer[J]. J Clin Oncol 2002; 20:1562-9.
7. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 1988; 241:1667-9.
8. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuxa RL. Attenuated multi- Mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1:938-943.
9. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9:967-78.
10. Shah AC, Benos D, Gillespie GY, Markert JM. Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 2003; 65:203-26.
11. Lou E. Oncolytic viral therapy and immunotherapv of malignant brain tumors: Two potential new approaches of translational research. Ann Med 2004; 36:2-8.
12. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250:1262-6.
13. Bolovan CA, Sawtell NM, Thompson RL. ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J Virol 1994; 68:48-55.
14. Ping Lan, Changyuan Dong, Yipeng Qi *, Gengfu Xiao, Feng Xue. Gene therapy for mice sarcoma with oncolytic herpes simplex Virus-1 lacking the apoptosis-inhibiting gene, icp34.5. J Biochem Mol Biol 2003; 36:379-86.
15. Yamamura H, Hashio M, Noguchi M, Sugenoya Y, Osakada M, Hirano N, Sasaki Y, Yoden T, Awata N, Araki N, Tatsuta M, Miyatake SI, Takahashi K. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res 2001; 61:3969-77.
16. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B, Whitley RJ. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998; 5:121-30.
17. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J Infect Dis 1988; 158:602-14.
18. Roizman B, Markovitz N. Herpes simplex virus virulence: The functions of the gamma (1)34.5 gene. J Neurovirol 1997; 3:S1-2.
19. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensible for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62:196-205.
20. Jia WW, McDermott M, Goldie J, Cynader M, Tan J, Tufaro F. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1 [see comments]. J Natl Cancer Inst 1994; 86:1209-15.
21. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995; 55:4752-6.
22. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 1997; 4:222-8.
23. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, Rizk NP, Molnar-Kimber KL, Brown SM, MacLean AR, Litzky LA, Fraser NW, Albelda SM, Kaiser LR. Use of a replication-restricted' herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997; 57:466-71.
24. Chou J, Roizman B. The gamma 34.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci USA 1992; 89:3266-70.
25. Chung RY, Saeki Y, Chiocca EA. B-Myb promoter retargeting of herpes simplex virus γ 34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 1999; 73:7556-64.
26. Nakamura H, Kasuya H, Mullen JT, Yoon SS, Pawlik TM, Chandrasekhar S, Donahue JM, Chiocca EA, Chung RY, Tanabe KK. Regulation of herpes simplex virus γ(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2002; 109:871-82.
27. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Martero AM, Prasad M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938-46.
28. Panis Y, Ribeiro J, Chretien Y, Nordlinger B. Dormant liver metastases: An experimental study. Br J Surg 1992; 79:221-3.
29. Fong Y, Kemeny N, Paty P, Blumgart LH, Cohen AM. Treatment of colorectal cancer: Hepatic metastasis. Semin Surg Onco 1996; 12:219-52.